Pharma Companies Use Non-Cash Payments to Lure Staff
Salaries in the U.K. life sciences sector are static, but the range of non-monetary benefits being offered to staff is improving fast, according to a new salary survey.
Salaries in the U.K. life sciences sector are static, but the range of non-monetary benefits being offered to staff is improving fast, according to a new salary survey.
More companies are seeking to recruit and retain employees by focusing on areas like medical cover, gym membership, and life assurance, as they attempt to keep their workforce satisfied while the sector slowly recovers from the recent economic downturn, noted recruitment firm Clinical Professionals.
The report concludes that there has been a slight increase in employee satisfaction, with more than half of those earning at least £49,000 per annum ($80,240) reported as happy with their salary. This represents a slight drop from last year’s crossover point of £50,000. However, over half of respondents in every field of life sciences (other than medical writing) are reported as looking for a new role. This was particularly the case in high-end medical positions.
“The salary survey shows us that, as the war for talent returns to the sector, companies are thinking imaginatively in order to keep their employees satisfied, and rather than raising salaries, improving benefits seems to be a popular option,” said Clinical Professionals’ Group Managing Director, Yvette Cleland.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
